T
Tomoko Aoki
Researcher at Kindai University
Publications - 30
Citations - 501
Tomoko Aoki is an academic researcher from Kindai University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 11 publications receiving 186 citations.
Papers
More filters
Journal ArticleDOI
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo,Kazuomi Ueshima,S.L. Chan,Tomohiro Minami,Hirokazu Chishina,Tomoko Aoki,Masahiro Takita,Satoru Hagiwara,Yasunori Minami,Hiroshi Ida,Mamoru Takenaka,Toshiharu Sakurai,Tomohiro Watanabe,Masahiro Morita,Chikara Ogawa,Yoshiyuki Wada,Masafumi Ikeda,Hiroshi Ishii,Namiki Izumi,Naoshi Nishida +19 more
TL;DR: In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child–Pugh A liver function, lenvatinib provides a more favorable outcome than TACE.
Journal ArticleDOI
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Kazuomi Ueshima,Naoshi Nishida,Satoru Hagiwara,Tomoko Aoki,Tomohiro Minami,Hirokazu Chishina,Masahiro Takita,Yasunori Minami,Hiroshi Ida,Mamoru Takenaka,Toshiharu Sakurai,Tomohiro Watanabe,Masahiro Morita,Chikara Ogawa,Atsushi Hiraoka,Philip J. Johnson,Masatoshi Kudo +16 more
TL;DR: Patients with Child–Pugh score of 5 and ALBI grade 1 predicted a higher response rate and lower treatment discontinuation due to adverse events by lenvatinib treatment.
Journal ArticleDOI
Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.
Masahiro Morita,Naoshi Nishida,Kazuko Sakai,Tomoko Aoki,Hirokazu Chishina,Masahiro Takita,Hiroshi Ida,Satoru Hagiwara,Yasunori Minami,Kazuomi Ueshima,Kazuto Nishio,Yukari Kobayashi,Kazuhiro Kakimi,Masatoshi Kudo +13 more
TL;DR: The combined score including Wnt/β-catenin activation, CPS of PD-L1, and degree of CD8+ tumor-infiltrating lymphocytes (TILs) in HCC is informative for predicting the response to ICI in H CC cases.
Journal ArticleDOI
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
Tomoko Aoki,Masatoshi Kudo,Kazuomi Ueshima,Masahiro Morita,Hirokazu Chishina,Masahiro Takita,Satoru Hagiwara,Hiroshi Ida,Yasunori Minami,Masakatsu Tsurusaki,Naoshi Nishida +10 more
TL;DR: Lenvatinib demonstrated considerably high antitumor activity and good survival benefit with acceptable toxicity in patients with unresectable HCC when administered right after failure of PD-1/PD-L1 blockade.
Journal ArticleDOI
Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma
Tomoko Aoki,Naoshi Nishida,Kazuomi Ueshima,Masahiro Morita,Hirokazu Chishina,Masahiro Takita,Satoru Hagiwara,Hiroshi Ida,Yasunori Minami,Akira Yamada,Keitaro Sofue,Masakatsu Tsurusaki,Masatoshi Kudo +12 more
TL;DR: The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC.